Neuen and Gale break down groundbreaking insights on Alport syndrome and glomerular diseases, including RaDaR registry data.
Daniel Gale, PhD, MB BChir
Advertisement
Daniel Gale, PhD, MB BChir, is the director of the UK-based RaDaR Registry and the St Peter's Chair of Nephrology at University College London.
Articles by Daniel Gale, PhD, MB BChir
An analysis of the VALIANT trial provides insight into the benefits of pegcetacoplan in patients with C3G and IC-MPGN.
A RaDaR analysis from ERA 2025 provides insight into predictors of disease progression, outcomes in patients with Alport syndrome.
A study presented at ERA 2025 validates the use of proteinuria as a surrogate endpoint for FSGS clinical trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Navigating Emotional Burden in IBD
2
Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD
3
Open Communication Between Patients and Providers in IBD
4
Linaclotide in Pediatric IBS-C—Evidence, Indications, and Practical Use
5